Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) – Drugs In Development, 2024 report and make more profitable business decisions.
Laminin alpha 2–related muscular dystrophy (LAMA2-MD) is a congenital muscular dystrophy (CMD) that causes muscle weakness and wasting. It is caused by harmful genetic changes in the LAMA2 gene, which is necessary for the proper functioning of skeletal and heart muscles. Symptoms include postnatal hypotonia, weak cry, reduced spontaneous movements, facial weakness, macroglossia, protruding tongue, and progressive limitation of extraocular movements. Diagnosis includes blood tests to measure level of creatine kinase (CK) and EMG for electrical activity in muscles. Treatment options include physical and occupational therapy, speech therapy, and surgery.
The Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) drugs in development market research report provide comprehensive information on the therapeutics under development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Constant Therapeutics LLCModalis Therapeutics Corp
Myocea Inc
Prothelia Inc
SEAL Therapeutics AG
Table of Contents
Table
Figures
Frequently asked questions